Targeting the Interplay Between Myeloma Cells and the Bone Marrow Microenvironment in Myeloma

Overview

Journal Int J Hematol

Specialty Hematology

Date 2011 Oct 19

PMID 22005835

Citations 36

Authors

Masahiro Abe

Affiliations

Soon will be listed here.

Abstract

Cellular interplay in the bone marrow (BM) microenvironment in multiple myeloma (MM) mediates MM growth and the formation of bone-destructive lesions. MM cells show enhanced osteoclastogenesis, and stimulate angiogenesis in concert with BM stromal cells and osteoclasts, whereas they suppress osteoblastic differentiation, leading to devastating bone destruction and the rapid loss of bone. Importantly, osteoclasts, vascular endothelial cells, and BM stromal cells with defective osteoblastic differentiation create a cellular microenvironment suitable for MM growth and survival and confer a drug resistance to MM cells, which can be construed as the "MM niche". Therefore, the MM niche must be targeted and disrupted to improve the efficacy of anti-tumor treatment and prevent the progression of bone disease in MM. Clarifying molecular mechanisms leading to the formation of the MM niche along with bone disease will help in the development of novel approaches targeting the interplay between MM cells and the BM microenvironment.

Citing Articles

Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review.

Schutt J, Brinkert K, Plis A, Schenk T, Brioli A Cancer Drug Resist. 2024; 7:26.

PMID: 39050883 PMC: 11267153. DOI: 10.20517/cdr.2024.39.

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche.

Solimando A, Malerba E, Leone P, Prete M, Terragna C, Cavo M Front Oncol. 2022; 12:973836.

PMID: 36212502 PMC: 9533079. DOI: 10.3389/fonc.2022.973836.

The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expression.

Smesny Trtkova K, Luzna P, Drozdkova D, Cizkova K, Janovska L, Gursky J Mol Med Rep. 2022; 26(4).

PMID: 36043519 PMC: 9471560. DOI: 10.3892/mmr.2022.12837.

Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.

Xie Y, Wang Y, Xu Z, Lu Y, Song D, Gao L J Biomed Sci. 2022; 29(1):32.

PMID: 35546402 PMC: 9097096. DOI: 10.1186/s12929-022-00813-2.

Myeloma-Bone Interaction: A Vicious Cycle via TAK1-PIM2 Signaling.

Harada T, Hiasa M, Teramachi J, Abe M Cancers (Basel). 2021; 13(17).

PMID: 34503251 PMC: 8431187. DOI: 10.3390/cancers13174441.

References

Edwards C, Edwards J, Lwin S, Esparza J, Oyajobi B, McCluskey B . Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood. 2007; 111(5):2833-42. PMC: 2254537. DOI: 10.1182/blood-2007-03-077685. View

Lee J, Chung H, Ehrlich L, Jelinek D, Callander N, Roodman G . IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 2003; 103(6):2308-15. DOI: 10.1182/blood-2003-06-1992. View

Delforge M, Terpos E, Richardson P, Shpilberg O, Khuageva N, Schlag R . Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol. 2011; 86(5):372-84. DOI: 10.1111/j.1600-0609.2011.01599.x. View

Fonseca R, Trendle M, Leong T, Kyle R, Oken M, Kay N . Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol. 2000; 109(1):24-9. DOI: 10.1046/j.1365-2141.2000.01960.x. View

Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D . Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol. 2004; 125(1):38-41. DOI: 10.1111/j.1365-2141.2004.04864.x. View

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B . The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483-94. DOI: 10.1056/NEJMoa030847. View

Moon R, Brown J, Torres M . WNTs modulate cell fate and behavior during vertebrate development. Trends Genet. 1997; 13(4):157-62. DOI: 10.1016/s0168-9525(97)01093-7. View

Ehrlich L, Chung H, Ghobrial I, Choi S, Morandi F, Colla S . IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005; 106(4):1407-14. DOI: 10.1182/blood-2005-03-1080. View

Haaber J, Abildgaard N, Knudsen L, Dahl I, Lodahl M, Thomassen M . Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol. 2007; 140(1):25-35. DOI: 10.1111/j.1365-2141.2007.06871.x. View

10.

Gunn W, Conley A, Deininger L, Olson S, Prockop D, Gregory C . A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2005; 24(4):986-91. DOI: 10.1634/stemcells.2005-0220. View

11.

Anderson K, Carrasco R . Pathogenesis of myeloma. Annu Rev Pathol. 2011; 6:249-74. DOI: 10.1146/annurev-pathol-011110-130249. View

12.

Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T . Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab. 2008; 27(1):16-23. DOI: 10.1007/s00774-008-0012-z. View

13.

Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K . RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 1999; 253(2):395-400. DOI: 10.1006/bbrc.1998.9788. View

14.

Yaccoby S, Wezeman M, Zangari M, Walker R, Cottler-Fox M, Gaddy D . Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006; 91(2):192-9. PMC: 1592551. View

15.

Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S . Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002; 100(6):2195-202. View

16.

Xie Y, Xu K, Linn D, Yang X, Guo Z, Shimelis H . The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2007; 283(6):3349-3356. DOI: 10.1074/jbc.M707773200. View

17.

Drew M, Barker H, Ball J, Pearson C, Cook G, Franklin I . Very late antigen (VLA) expression by normal and neoplastic human plasma cells; including an assessment of antibodies submitted to the Vth International Workshop on Leucocyte Differentiation Antigens using human myeloma cell lines. Leuk Res. 1996; 20(7):619-24. DOI: 10.1016/0145-2126(95)00097-6. View

18.

Dhodapkar M, Singh J, Mehta J, Fassas A, Desikan K, Perlman M . Anti-myeloma activity of pamidronate in vivo. Br J Haematol. 1998; 103(2):530-2. DOI: 10.1046/j.1365-2141.1998.00976.x. View

19.

Hjertner O, Torgersen M, Seidel C, Hjorth-Hansen H, Waage A, Borset M . Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood. 1999; 94(11):3883-8. View

20.

Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy Jr J . Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2006; 109(5):2106-11. PMC: 1801040. DOI: 10.1182/blood-2006-09-047712. View